Premium
Vitamin D and type 2 diabetes mellitus
Author(s) -
Cangoz S.,
Chang Y.Y.,
Chempakaseril S. J.,
Guduru R. C.,
Huynh L. M.,
John J. S.,
John S. T.,
Joseph M. E.,
Judge R.,
Kimmey R.,
Kudratov K.,
Lee P. J.,
Madhani I. C.,
Shim P. J.,
Singh S.,
Singh S.,
Ruchalski C.,
Raffa R. B.
Publication year - 2013
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12026
Subject(s) - medicine , vitamin d and neurology , hypovitaminosis , vitamin d deficiency , vitamin , diabetes mellitus , type 2 diabetes mellitus , physiology , endocrinology , intensive care medicine
Summary What is known and Objective The deleterious effect of vitamin D deficiency on bone health has long been known. More recent studies suggest a deleterious effect of low vitamin D (hypovitaminosis D ) on general health. And specific studies propose an association between hypovitaminosis D and the aetiology and progression of type 2 diabetes ( T 2 DM ). Given a commonly assumed lack of toxicity of vitamin D , routine measurement of plasma vitamin D and supplementation is rapidly becoming accepted general practice. Comment Authoritative practice guidelines have raised the level of vitamin D that is to be considered minimal for optimum health. This recommendation was based on a wealth of information and definitive evidence for skeletal benefits of vitamin D , but there was a lack of compelling evidence that hypovitaminosis D is causally related to extra‐skeletal health outcomes such as diabetes. Hence, vitamin D supplementation for the purpose of achieving a level consistent with good health is evidence based, but measurement and supplementation for the purpose of preventing or treating T 2 DM is not. What is new and Conclusion Although the maintenance of adequate vitamin D levels is desirable for all patients, we conclude that routine measurement of vitamin D level in every patient or initiating high‐dose supplementation for the purpose of preventing or treating T 2 DM is not evidence based.